Tempus confirmed acquisition of pharmacogenetics assets from OneOme, the Mayo Clinic spin‑out that recently dissolved amid financial difficulties. Tempus said the deal includes OneOme’s RightMed PGx test and customer partnerships, which could accelerate Tempus’ push into pharmacogenomics and broaden its clinical testing footprint across health systems. Industry experts told GenomeWeb the value lies in OneOme’s commercial relationships and reporting format rather than proprietary technology; Tempus has been active on the M&A front this year to expand its molecular testing menu. The transaction aims to provide continuity for clinics and patients left without PGx services after OneOme’s abrupt shutdown. Clarification: Pharmacogenetics (PGx) testing maps DNA variants that affect drug metabolism and response, guiding medication selection and dosing.